OneSource Specialty Pharma Limited (ONESOURCE) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ONESOURCE Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

OneSource

Specialty Pharma Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ONESOURCE Stock 12 Month Forecast

Average Price Target

₹2,000.00

▲(3.44%Upside)

Based on 1 Wall Street analysts offering 12 month price targets for OneSource Specialty Pharma Limited in the last 3 months. The average price target is ₹2,000.00 with a high forecast of ₹2,000.00 and a low forecast of ₹2,000.00. The average price target represents a 3.44% change from the last price of ₹1,933.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1235":"₹1,235","1618":"₹1,618","2001":"₹2,001","1426.5":"₹1,426.5","1809.5":"₹1,809.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1235,1426.5,1618,1809.5,2001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1887.75,1896.3846153846155,1905.0192307692307,1913.6538461538462,1922.2884615384614,1930.923076923077,1939.5576923076924,1948.1923076923076,1956.826923076923,1965.4615384615386,1974.0961538461538,1982.7307692307693,1991.3653846153845,{"y":2000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1887.75,1896.3846153846155,1905.0192307692307,1913.6538461538462,1922.2884615384614,1930.923076923077,1939.5576923076924,1948.1923076923076,1956.826923076923,1965.4615384615386,1974.0961538461538,1982.7307692307693,1991.3653846153845,{"y":2000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1887.75,1896.3846153846155,1905.0192307692307,1913.6538461538462,1922.2884615384614,1930.923076923077,1939.5576923076924,1948.1923076923076,1956.826923076923,1965.4615384615386,1974.0961538461538,1982.7307692307693,1991.3653846153845,{"y":2000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1617.45,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1617.45,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1573.65,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1236.85,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1629,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1623.35,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1623.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1887.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹2,000

Average Price Target₹2,000

Lowest Price Target₹2,000

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anshuman Gupta CFAInvestec

Investec

₹2,000

Buy

3.44%

Upside

Initiated

05/15/25

Investec Starts OneSource Specialty Pharma Ltd (ONESOURC:IN) at BuyInvestec analyst Anshuman Gupta initiates coverage on OneSource Specialty Pharma Ltd (ONESOURC:IN) with a Buy rating and a price target of INR2,000.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anshuman Gupta CFAInvestec

Investec

₹2,000

Buy

3.44%

Upside

Initiated

05/15/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering OneSource Specialty Pharma Limited

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+27.20%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +27.20% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+25.60%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +25.60% per trade.

1 Year

Anshuman Gupta CFAInvestec

Success Rate

1/1 ratings generated profit

Average Return

+25.60%

initiated a buy rating 2 months ago

Copying Anshuman Gupta CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.60% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+25.60%

initiated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONESOURCE Analyst Recommendation Trends

Rating

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ONESOURCE has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ONESOURCE average Analyst price target in the past 3 months is 2,000.00.

Each month's total comprises the sum of three months' worth of ratings.

ONESOURCE Financial Forecast

ONESOURCE Earnings Forecast

The previous quarter’s earnings for ONESOURCE were ₹9.00.

No data currently available

ONESOURCE Sales Forecast

Currently, no sales data available.

ONESOURCE Stock Forecast FAQ

What is IN:ONESOURCE’s average 12-month price target, according to analysts?

Based on analyst ratings, OneSource Specialty Pharma Limited’s 12-month average price target is 2,000.00.

What is IN:ONESOURCE’s upside potential, based on the analysts’ average price target?

OneSource Specialty Pharma Limited has 3.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OneSource Specialty Pharma Limited a Buy, Sell or Hold?

OneSource Specialty Pharma Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is OneSource Specialty Pharma Limited’s share price target?

The average share price target for OneSource Specialty Pharma Limited is 2,000.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹2,000.00 ,and the lowest forecast is ₹2,000.00. The average share price target represents 3.44% Increase from the current price of ₹1,933.45.

What do analysts say about OneSource Specialty Pharma Limited?

OneSource Specialty Pharma Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of OneSource Specialty Pharma Limited?

To buy shares of IN:ONESOURCE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

OneSource Specialty Pharma Limited (ONESOURCE) Stock Forecast & Price Target

ONESOURCE Analyst Ratings

ONESOURCE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering OneSource Specialty Pharma Limited

ONESOURCE Analyst Recommendation Trends

ONESOURCE Financial Forecast

ONESOURCE Earnings Forecast

ONESOURCE Sales Forecast

ONESOURCE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts